# Fujian Shengdi Pharmaceutical Co., Ltd.: Phase 1 study closed enrollment, 48 enrolled (Overweight and Obesity)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Fujian Shengdi Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity |
| NCT ID | NCT07559136 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Overweight and Obesity |
| Intervention types | drug |
| Target enrollment | 48 |
| Site countries | China |
| Posted | 2026-04-30 |
| Planned start | 2026-06-12 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07559136). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.